Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lélia Delamarre

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Seminars in Immunology|November 30, 2023
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapyChristine Moussion, Lélia Delamarre
Frontiers in Immunology|June 10, 2014
Dendritic cell-targeted vaccinesLillian Cohn, Lélia Delamarre
Seminars in Immunology|March 8, 2011
Harnessing dendritic cells for immunotherapyLélia Delamarre, Ira Mellman
Cell Reports. Medicine|October 19, 2022
Peroxynitrite promotes immune evasion by reducing tumor antigenicityAude-Hélène Capietto, Lélia Delamarre
Nature Reviews. Cancer|March 22, 2021
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasionSuchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
International Journal of Molecular Sciences|September 9, 2022
Sources of Cancer Neoantigens beyond Single-Nucleotide VariantsAude-Hélène Capietto, Reyhane Hoshyar, Lélia Delamarre
Molecular & Cellular Oncology|May 12, 2020
Cancer neoantigens and immunogenicity: mutation position mattersAude-Hélène Capietto, Suchit Jhunjhunwala, Lélia Delamarre
Seminars in Immunology|April 7, 2023
The peptide woods are lovely, dark and deep: Hunting for novel cancer antigensDaniel Oreper, Susan Klaeger, Suchit Jhunjhunwala, et al.
The Journal of Experimental Medicine|August 16, 2006
Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysisLélia Delamarre, Rachael Couture, Ira Mellman, et al.
Nature Reviews. Immunology|October 21, 2024
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironmentFaezzah Baharom, Dalton Hermans, Lélia Delamarre, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Seminars in Immunology|November 30, 2023
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapyChristine Moussion, Lélia Delamarre
Frontiers in Immunology|June 10, 2014
Dendritic cell-targeted vaccinesLillian Cohn, Lélia Delamarre
Seminars in Immunology|March 8, 2011
Harnessing dendritic cells for immunotherapyLélia Delamarre, Ira Mellman
Cell Reports. Medicine|October 19, 2022
Peroxynitrite promotes immune evasion by reducing tumor antigenicityAude-Hélène Capietto, Lélia Delamarre
Nature Reviews. Cancer|March 22, 2021
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasionSuchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
International Journal of Molecular Sciences|September 9, 2022
Sources of Cancer Neoantigens beyond Single-Nucleotide VariantsAude-Hélène Capietto, Reyhane Hoshyar, Lélia Delamarre
Molecular & Cellular Oncology|May 12, 2020
Cancer neoantigens and immunogenicity: mutation position mattersAude-Hélène Capietto, Suchit Jhunjhunwala, Lélia Delamarre
Seminars in Immunology|April 7, 2023
The peptide woods are lovely, dark and deep: Hunting for novel cancer antigensDaniel Oreper, Susan Klaeger, Suchit Jhunjhunwala, et al.
The Journal of Experimental Medicine|August 16, 2006
Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysisLélia Delamarre, Rachael Couture, Ira Mellman, et al.
Nature Reviews. Immunology|October 21, 2024
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironmentFaezzah Baharom, Dalton Hermans, Lélia Delamarre, et al.
Pageof 4